Eli Lilly
Last updated Jun 27, 2026
Evidence Sources
12
Competitive Findings
2
Portfolio Developments
16
Regulatory Precedents
8
Clinical Programs
2
Confidence Coverage
68%
Audit
- Competitor findings: 2
- Portfolio developments: 16
- Self-competition findings removed: 21
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Oncology
- mTOR Inhibitor
- Diabetes
- GLP-1
- Hematology
Highest priority development: FDA Acceptance of Supplement for AFINITOR (Everolimus) by Novartis
Portfolio development
FDA Acceptance of Supplement for AFINITOR (Everolimus) by Novartis is an owned Eli Lilly portfolio development in Oncology · mTOR Inhibitor.
Competitive pressure: High
Portfolio impact: High
Evidence coverage: 68%
Active Signals
75
Investigate Priority
11
Opportunity Score
23952
Buyer Quality
10 · Enterprise
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 27, 2026Score 327FDA Approves Supplemental Application for IBRANCE (Palbociclib)
Oncology · CDK4/6 Inhibitor
- InvestigateJun 16, 2026Score 327Lilly's VERVE-102 Shows Significant LDL-C Reduction in Phase 1b Trial
Cardiovascular · Gene Editing
- MonitorJul 20, 2026Score 326Merck's MK-2214 Trial Aims to Slow Tau Spread in Early Alzheimer's Disease
Neurology · Alzheimer's Disease
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
- Low Confidence · 0%Sources (3)Humanexa SignalsFDAPortfolio
- Low Confidence · 0%Sources (3)LillyClinicalTrials.govPortfolio
- Low Confidence · 0%Sources (3)Humanexa SignalsClinicalTrials.govPortfolio
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
- Lilly (named in signal competitive context)Moderate Confidence · 72%
Elevated competitive pressure
Sources (2)FDACompetitiva - Lilly to present Phase 3 study of Retevmo in RET fusion-positive NSCLC at ASCO 2026High Confidence · 95%
Potential competitive pressure
Sources (2)LillyCompetitiva
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumorsHigh Confidence · 95%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Other | Cancer Accelerated ApprovalsModerate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — TEGRETOL (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — GLEEVEC (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
- Lilly (named in signal competitive context)Moderate Confidence · 68%
Competitive clinical program activity indicated
Sources (2)CompetitivaClinicalTrials.gov - Lilly to present Phase 3 study of Retevmo in RET fusion-positive NSCLC at ASCO 2026Moderate Confidence · 68%
Competitive clinical program activity indicated
Sources (2)CompetitivaClinicalTrials.gov
Capital Markets
SEC filings, IPO activity, and capital markets events from the Business Intelligence Layer.
No capital markets intelligence is available yet.
Financing History
Venture funding, follow-on offerings, PIPE financings, and debt financing.
No financing history is available yet.
Licensing & Partnerships
Licensing agreements, strategic partnerships, and distribution deals.
No licensing or partnership activity is available yet.
M&A Activity
Acquisitions, mergers, and divestitures.
No M&A activity is available yet.
Investor Activity
Earnings releases, investor presentations, and conference appearances.
No investor activity is available yet.
Executive Changes
CEO appointments, board changes, and leadership restructuring.
No executive changes are available yet.
Business Timeline
Chronological business intelligence events across financing, licensing, M&A, and commercial strategy.
No business timeline events are available yet.
Strategic Signals
Higher-order strategic intelligence fused from regulatory, scientific, business, and competitive events. Signals answer what it means — not just what happened.
Strategic signals will appear once sufficient event convergence is detected.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
- InvestigateScore 327Lilly's VERVE-102 Shows Significant LDL-C Reduction in Phase 1b Trial
Cardiovascular · Gene Editing
- EscalateScore 324Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants
Infectious Disease · Respiratory Syncytial Virus (RSV)
- InvestigateScore 321Lilly's Jaypirca recommended for EU approval in CLL across all therapy lines
Hematology · CLL
- InvestigateScore 320Lilly to acquire Ajax Therapeutics for myelofibrosis and polycythemia vera
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Eli Lilly right now?
- Which regulatory precedents should Eli Lilly monitor in Oncology and mTOR Inhibitor?
- How does Lilly compare to the nearest competitive programs?
- What signals require immediate investigation for Eli Lilly?
- Summarize the strategic implications of recent developments for Eli Lilly.
- Where is the greatest uncertainty in Eli Lilly's competitive positioning?